Logo image of AZTR

AZITRA INC (AZTR) Stock Fundamental Analysis

NYSEARCA:AZTR - NYSE Arca - US05479L2034 - Common Stock - Currency: USD

0.3642  +0.01 (+4.06%)

After market: 0.3675 +0 (+0.91%)

Fundamental Rating

2

AZTR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. AZTR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AZTR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AZTR has reported negative net income.
In the past year AZTR has reported a negative cash flow from operations.
AZTR Yearly Net Income VS EBIT VS OCF VS FCFAZTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

AZTR's Return On Assets of -92.34% is on the low side compared to the rest of the industry. AZTR is outperformed by 72.91% of its industry peers.
AZTR has a Return On Equity (-112.04%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -92.34%
ROE -112.04%
ROIC N/A
ROA(3y)-174.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AZTR Yearly ROA, ROE, ROICAZTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

AZTR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AZTR Yearly Profit, Operating, Gross MarginsAZTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

AZTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
AZTR has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, AZTR has an improved debt to assets ratio.
AZTR Yearly Shares OutstandingAZTR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M 10M
AZTR Yearly Total Debt VS Total AssetsAZTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.64, we must say that AZTR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AZTR (-8.64) is worse than 70.94% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that AZTR is not too dependend on debt financing.
AZTR has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.64
ROIC/WACCN/A
WACC8.83%
AZTR Yearly LT Debt VS Equity VS FCFAZTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 5.58 indicates that AZTR has no problem at all paying its short term obligations.
AZTR has a Current ratio of 5.58. This is comparable to the rest of the industry: AZTR outperforms 58.65% of its industry peers.
A Quick Ratio of 5.58 indicates that AZTR has no problem at all paying its short term obligations.
AZTR's Quick ratio of 5.58 is in line compared to the rest of the industry. AZTR outperforms 59.18% of its industry peers.
Industry RankSector Rank
Current Ratio 5.58
Quick Ratio 5.58
AZTR Yearly Current Assets VS Current LiabilitesAZTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

AZTR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -127.06%.
The Revenue for AZTR has decreased by -84.34% in the past year. This is quite bad
Measured over the past years, AZTR shows a quite strong growth in Revenue. The Revenue has been growing by 16.85% on average per year.
EPS 1Y (TTM)-127.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.09%
Revenue 1Y (TTM)-84.34%
Revenue growth 3Y16.85%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, AZTR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.73% on average per year.
The Revenue is expected to grow by 73.27% on average over the next years. This is a very strong growth
EPS Next Y95.94%
EPS Next 2Y40.91%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year-68.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AZTR Yearly Revenue VS EstimatesAZTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
AZTR Yearly EPS VS EstimatesAZTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AZTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AZTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AZTR Price Earnings VS Forward Price EarningsAZTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZTR Per share dataAZTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as AZTR's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.91%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AZTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZITRA INC

NYSEARCA:AZTR (2/26/2025, 7:26:25 PM)

After market: 0.3675 +0 (+0.91%)

0.3642

+0.01 (+4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners3.59%
Inst Owner Change-71.9%
Ins Owners0.18%
Ins Owner Change0%
Market Cap6.67M
Analysts82.86
Price Target3.57 (880.23%)
Short Float %4.64%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.41%
Min EPS beat(2)-3.52%
Max EPS beat(2)54.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)93.48%
EPS NY rev (1m)-95.24%
EPS NY rev (3m)-95.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-89.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.43
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-7.48
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.01
BVpS0.44
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.34%
ROE -112.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-174.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.58
Quick Ratio 5.58
Altman-Z -8.64
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)219.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)149.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.09%
EPS Next Y95.94%
EPS Next 2Y40.91%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)-84.34%
Revenue growth 3Y16.85%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-68.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.27%
EBIT growth 1Y-43.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.46%
OCF growth 3YN/A
OCF growth 5YN/A